Akiram Therapeutics to Present First Clinical Results of AKIR001
Swedish biotech firm Akiram Therapeutics will present initial clinical data from its lead drug candidate AKIR001 at the EANM 2026 Congress. Preliminary findings indicate a favorable safety profile and sustained tumor retention.
Swedish clinical-stage biotechnology company Akiram Therapeutics announced that preliminary clinical data from its ongoing Phase I trial of ¹⁷⁷Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17-21. The study evaluates the drug candidate in patients with unresectable or metastatic CD44v6-positive solid tumors who have exhausted standard treatment options.
At the data cut-off, eight patients had been treated. No dose-limiting toxicities were observed, and treatment-related adverse events were Grade 1-2. Four patients received repeat treatment after the initial administration. Quantitative imaging demonstrated sustained tumor retention of ¹⁷⁷Lu-AKIR001, with clearance from blood and normal tissues.
Low CD44v6 expression, as determined by immunohistochemistry (IHC), was consistently associated with low absorbed tumor doses. These findings highlight the potential of IHC for patient stratification and selection. The company noted that the ability for patients to receive repeat treatment is an important consideration for ongoing development.
Additionally, a preclinical study evaluating AKIR001 and a derived scFv antibody format for theranostic applications in bladder cancer was also selected for presentation. This research expands the evaluation of Akiram's CD44v6-targeting platform to a new tumor type and antibody format.